Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository

Imagem de Miniatura
Arquivos
art_KASSANJEE_Independent_assessment_of_candidate_HIV_incidence_assays_on_2014.PDF (936.16 KB)
Citações na Scopus
122
Tipo de produção
article
Data de publicação
2014
DOI
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
KASSANJEE, Reshma
PILCHER, Christopher D.
KEATING, Sheila M.
FACENTE, Shelley N.
MCKINNEY, Elaine
PRICE, Matthew A.
MARTIN, Jeffrey N.
LITTLE, Susan
HECHT, Frederick M.
Citação
AIDS, v.28, n.16, p.2439-2449, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: Cross-sectional HIV incidence surveillance, using assays that distinguish `recent' from `nonrecent' infections, has been hampered by inadequate performance and characterization of incidence assays. In this study, the Consortium for the Evaluation and Performance of HIV Incidence Assays presents results of the first independent evaluation of five incidence assays (BED, Limiting Antigen Avidity, Less-sensitive Vitros, Vitros Avidity and BioRad Avidity). Design: A large repository of diverse specimens from HIV-positive patients was established, multiple assays were run on 2500 selected specimens, and data were analyzed to estimate assay characteristics relevant for incidence surveillance. Methods: The mean duration of recent infection (MDRI, average time `recent' while infected for less than some time cut-off T) was estimated from longitudinal data on seroconverters by regression. The false-recent rate (FRR, probability of testing `recent' when infected for longer than T) was explored by measuring the proportions of `recent' results in various subsets of patients. Results: Assays continue to fail to attain the simultaneously large MDRI and small FRR demanded by existing performance guidelines. All assays produce high FRRs amongst virally suppressed patients (>40%), including elite controllers and treated patients. Conclusions: Results from this first independent evaluation provide valuable information about the current performance of assays, and suggest the need for further optimization. Variation of `recent'/`nonrecent' thresholds and the use of multiple antibody-maturation assays, as well as other biomarkers, can now be explored, using the rich data generated by the Consortium for the Evaluation and Performance of HIV Incidence Assays. Consistently high FRRs amongst those virally suppressed suggest that viral load will be a particularly valuable supplementary marker. Video abstract: http://links.lww.com/QAD/A569 (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
Palavras-chave
biomarkers, HIV, incidence assays, incidence estimation, recent infection
URI
https://observatorio.fm.usp.br/handle/OPI/8324
Referências
  1. Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469
  2. [Anonymous], GUIDELINES USE ANTIR
  3. Bill & Melinda Gates Foundation Letters of Inquiry (LOI), NEW BIOM HIV INC MEA
  4. Bollinger RC, 1997, JAMA-J AM MED ASSOC, V278, P2085, DOI 10.1001/jama.278.23.2085
  5. Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205
  6. Brookmeyer R, 2013, AM J EPIDEMIOL, V177, P264, DOI 10.1093/aje/kws436
  7. BROOKMEYER R, 1995, AM J EPIDEMIOL, V141, P166
  8. Costa PR, 2014, 2014 C RETR OPP INF
  9. Curtis KA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064201
  10. Daar ES, 2001, ANN INTERN MED, V134, P25
  11. Duong YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033328
  12. Efron B, 1993, MONOGRAPHS STAT APPL, V57
  13. Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/01.aids.0000076308.76477.b8
  14. Hecht FM, 2002, AIDS, V16, P1119, DOI 10.1097/00002030-200205240-00005
  15. Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
  16. *INC ASS CRIT PATH, 2011, PLOS MED, V0008
  17. Jain V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015510
  18. Kassanjee R, 2013, 20 C RETR OPP INF AT
  19. Kassanjee R, 2014, AIDS RES HUM RETROV, V30, P45, DOI [10.1089/AID.2013.0113, 10.1089/aid.2013.0113]
  20. Kassanjee R, 2012, EPIDEMIOLOGY, V23, P721, DOI 10.1097/EDE.0b013e3182576c07
  21. Kassanjee R, 2013, SAT SESS 20 C RETR O
  22. Keating SM, 2012, J CLIN MICROBIOL, V50, P3968, DOI 10.1128/JCM.01454-12
  23. Killian MS, 2006, AIDS RES HUM RETROV, V22, P640, DOI 10.1089/aid.2006.22.640
  24. Laeyendecker O, 2013, J INFECT DIS, V207, P232, DOI 10.1093/infdis/jis659
  25. Le Vu S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039872
  26. Lee HY, 2009, J THEOR BIOL, V261, P341, DOI 10.1016/j.jtbi.2009.07.038
  27. Lindback S, 2000, AIDS, V14, P2333, DOI 10.1097/00002030-200010200-00014
  28. Masciotra S, 2010, 17 C RETR OPP INF SA
  29. Masciotra S, 2011, J CLIN VIROL, V52, pS17, DOI 10.1016/j.jcv.2011.09.011
  30. Mastro TD, 2010, J HIV AIDS SURVEILL, V2, P1
  31. Mehrotra DV, 2003, BIOMETRICS, V59, P441, DOI 10.1111/1541-0420.00051
  32. Morris SR, 2010, ANN INTERN MED, V152, P778, DOI 10.7326/0003-4819-152-12-201006150-00005
  33. Parekh BS, 2002, AIDS RES HUM RETROV, V18, P295, DOI 10.1089/088922202753472874
  34. Pilcher CD, 2001, JAMA-J AM MED ASSOC, V286, P1713, DOI 10.1001/jama.286.14.1713
  35. Powers KA, 2007, AIDS, V21, P2237
  36. Price MA, 2011, AIDS RES HUM RETROV, V27, P5, DOI 10.1089/aid.2010.0030
  37. Schacker T, 1996, ANN INTERN MED, V125, P257
  38. Sedia Biosciences Corporation, 2012, SED HIV 1 LAG AV EIA
  39. Sedia Biosciences Corporation, 2013, SED BED HIV 1 INC EI
  40. Sedia Biosciences Corporation, 2013, SED HIV 1 LAG AV EIA
  41. South African Department of Health, S AFR ANT TREATM GUI
  42. UNAIDS/WHO working group on global HIV/AIDS and STI surveillance, 2011, US ASS REC INF EST H
  43. Wendel SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055525
  44. WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/60
Artigos e Materiais de Revistas Científicas - ODS/03